The Experts below are selected from a list of 231 Experts worldwide ranked by ideXlab platform
Ivan K. Baykov - One of the best experts on this subject based on the ideXlab platform.
-
A protective chimeric antibody to tick-borne Encephalitis Virus
Vaccine, 2014Co-Authors: Ivan K. Baykov, Lvovich Eduard Matveev, Alexander B. Ryzhikov, Andrey L. Matveev, Oleg V. Stronin, Marat F. Kasakin, Vladimir A. Richter, Nina V. TikunovaAbstract:The efficiency of several mouse monoclonal antibodies (mAbs) specific to the tick-borne Encephalitis Virus (TBEV) glycoprotein E in post-exposure prophylaxis was assessed, and mAb14D5 was shown to be the most active of all those studied. It was proven that the hybridoma cell line 14D5 produced one immunoglobulin H chain and two L chains. They were used to construct chimeric antibodies ch14D5a and ch14D5b, the affinity constants of which were 2.6×1010M-1 and 1.0×107M-1, respectively, according to the SPR-based ProteOn biosensor assay. The neutralization index (IC50) of ch14D5a was 0.04μg/ml in the focus reduction neutralization test. In in vivo experiments, ch14D5a at a dose of 10μg/mouse resulted in a 100% survival of the mice infected with 240 LD50 of TBEV. This chimeric antibody is promising for further development of prevention and therapeutic drugs against TBEV. © 2014 Elsevier Ltd.
-
Chimeric antibodies against tick-borne Encephalitis Virus
Vaccine, 2010Co-Authors: Lev N. Levanov, Lvovich Eduard Matveev, Elena P. Goncharova, Leonid R. Lebedev, Alexander B. Ryzhikov, Tatyana E. Yun, Alexander N. Shvalov, Ivan K. Baykov, Tatyana A. Batanova, Lyudmila N. ShingarovaAbstract:Two chimeric antibodies (ch) 13D6 and 10C2 against the glycoprotein E of tick-borne Encephalitis Virus (TBEV) were constructed by fusing variable regions of murine monoclonal antibodies (Mabs) 13D6 and 10C2 to human constant regions. Monovalent analogues of these antibodies in format of single-chain antibodies (scFv or sc) were developed, as well. The ch13D6, ch10C2, sc13D6 and sc10C2 exhibited binding characteristics similar to parental Mabs. Only the ch13D6 and sc13D6 were able to neutralize TBEV infectivity in vitro. The in vitro neutralization provided by ch13D6 suggests that this antibody can be further developed into a potent prophylaxis and therapy for tick-borne Encephalitis (TBE) infection. © 2010 Elsevier Ltd.
Theodore G Andreadis - One of the best experts on this subject based on the ideXlab platform.
-
eastern equine Encephalitis Virus old enemy new threat
The New England Journal of Medicine, 2013Co-Authors: Philip M Armstrong, Theodore G AndreadisAbstract:Over the past decade, we have witnessed a sustained resurgence of eastern equine Encephalitis Virus activity within long-standing foci in the northeastern United States and northward expansion into regions where the Virus was historically rare or previously unknown.
Lyudmila N. Shingarova - One of the best experts on this subject based on the ideXlab platform.
-
Chimeric antibodies against tick-borne Encephalitis Virus
Vaccine, 2010Co-Authors: Lev N. Levanov, Lvovich Eduard Matveev, Elena P. Goncharova, Leonid R. Lebedev, Alexander B. Ryzhikov, Tatyana E. Yun, Alexander N. Shvalov, Ivan K. Baykov, Tatyana A. Batanova, Lyudmila N. ShingarovaAbstract:Two chimeric antibodies (ch) 13D6 and 10C2 against the glycoprotein E of tick-borne Encephalitis Virus (TBEV) were constructed by fusing variable regions of murine monoclonal antibodies (Mabs) 13D6 and 10C2 to human constant regions. Monovalent analogues of these antibodies in format of single-chain antibodies (scFv or sc) were developed, as well. The ch13D6, ch10C2, sc13D6 and sc10C2 exhibited binding characteristics similar to parental Mabs. Only the ch13D6 and sc13D6 were able to neutralize TBEV infectivity in vitro. The in vitro neutralization provided by ch13D6 suggests that this antibody can be further developed into a potent prophylaxis and therapy for tick-borne Encephalitis (TBE) infection. © 2010 Elsevier Ltd.
Lvovich Eduard Matveev - One of the best experts on this subject based on the ideXlab platform.
-
A protective chimeric antibody to tick-borne Encephalitis Virus
Vaccine, 2014Co-Authors: Ivan K. Baykov, Lvovich Eduard Matveev, Alexander B. Ryzhikov, Andrey L. Matveev, Oleg V. Stronin, Marat F. Kasakin, Vladimir A. Richter, Nina V. TikunovaAbstract:The efficiency of several mouse monoclonal antibodies (mAbs) specific to the tick-borne Encephalitis Virus (TBEV) glycoprotein E in post-exposure prophylaxis was assessed, and mAb14D5 was shown to be the most active of all those studied. It was proven that the hybridoma cell line 14D5 produced one immunoglobulin H chain and two L chains. They were used to construct chimeric antibodies ch14D5a and ch14D5b, the affinity constants of which were 2.6×1010M-1 and 1.0×107M-1, respectively, according to the SPR-based ProteOn biosensor assay. The neutralization index (IC50) of ch14D5a was 0.04μg/ml in the focus reduction neutralization test. In in vivo experiments, ch14D5a at a dose of 10μg/mouse resulted in a 100% survival of the mice infected with 240 LD50 of TBEV. This chimeric antibody is promising for further development of prevention and therapeutic drugs against TBEV. © 2014 Elsevier Ltd.
-
Chimeric antibodies against tick-borne Encephalitis Virus
Vaccine, 2010Co-Authors: Lev N. Levanov, Lvovich Eduard Matveev, Elena P. Goncharova, Leonid R. Lebedev, Alexander B. Ryzhikov, Tatyana E. Yun, Alexander N. Shvalov, Ivan K. Baykov, Tatyana A. Batanova, Lyudmila N. ShingarovaAbstract:Two chimeric antibodies (ch) 13D6 and 10C2 against the glycoprotein E of tick-borne Encephalitis Virus (TBEV) were constructed by fusing variable regions of murine monoclonal antibodies (Mabs) 13D6 and 10C2 to human constant regions. Monovalent analogues of these antibodies in format of single-chain antibodies (scFv or sc) were developed, as well. The ch13D6, ch10C2, sc13D6 and sc10C2 exhibited binding characteristics similar to parental Mabs. Only the ch13D6 and sc13D6 were able to neutralize TBEV infectivity in vitro. The in vitro neutralization provided by ch13D6 suggests that this antibody can be further developed into a potent prophylaxis and therapy for tick-borne Encephalitis (TBE) infection. © 2010 Elsevier Ltd.
Alexander B. Ryzhikov - One of the best experts on this subject based on the ideXlab platform.
-
A protective chimeric antibody to tick-borne Encephalitis Virus
Vaccine, 2014Co-Authors: Ivan K. Baykov, Lvovich Eduard Matveev, Alexander B. Ryzhikov, Andrey L. Matveev, Oleg V. Stronin, Marat F. Kasakin, Vladimir A. Richter, Nina V. TikunovaAbstract:The efficiency of several mouse monoclonal antibodies (mAbs) specific to the tick-borne Encephalitis Virus (TBEV) glycoprotein E in post-exposure prophylaxis was assessed, and mAb14D5 was shown to be the most active of all those studied. It was proven that the hybridoma cell line 14D5 produced one immunoglobulin H chain and two L chains. They were used to construct chimeric antibodies ch14D5a and ch14D5b, the affinity constants of which were 2.6×1010M-1 and 1.0×107M-1, respectively, according to the SPR-based ProteOn biosensor assay. The neutralization index (IC50) of ch14D5a was 0.04μg/ml in the focus reduction neutralization test. In in vivo experiments, ch14D5a at a dose of 10μg/mouse resulted in a 100% survival of the mice infected with 240 LD50 of TBEV. This chimeric antibody is promising for further development of prevention and therapeutic drugs against TBEV. © 2014 Elsevier Ltd.
-
Chimeric antibodies against tick-borne Encephalitis Virus
Vaccine, 2010Co-Authors: Lev N. Levanov, Lvovich Eduard Matveev, Elena P. Goncharova, Leonid R. Lebedev, Alexander B. Ryzhikov, Tatyana E. Yun, Alexander N. Shvalov, Ivan K. Baykov, Tatyana A. Batanova, Lyudmila N. ShingarovaAbstract:Two chimeric antibodies (ch) 13D6 and 10C2 against the glycoprotein E of tick-borne Encephalitis Virus (TBEV) were constructed by fusing variable regions of murine monoclonal antibodies (Mabs) 13D6 and 10C2 to human constant regions. Monovalent analogues of these antibodies in format of single-chain antibodies (scFv or sc) were developed, as well. The ch13D6, ch10C2, sc13D6 and sc10C2 exhibited binding characteristics similar to parental Mabs. Only the ch13D6 and sc13D6 were able to neutralize TBEV infectivity in vitro. The in vitro neutralization provided by ch13D6 suggests that this antibody can be further developed into a potent prophylaxis and therapy for tick-borne Encephalitis (TBE) infection. © 2010 Elsevier Ltd.